News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
239,785 Results
Type
Article (7398)
Company Profile (18)
Press Release (232368)
Multimedia
Podcasts (8)
Webinars (2)
Section
Business (63211)
Career Advice (301)
Deals (14787)
Drug Delivery (32)
Drug Development (36874)
Employer Resources (24)
FDA (6472)
Job Trends (4922)
News (122057)
Policy (11682)
Tag
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
Academia (572)
Accelerated approval (15)
Adcomms (8)
Allergies (68)
Alliances (14841)
ALS (68)
Alzheimer's disease (722)
Antibody-drug conjugate (ADC) (150)
Approvals (6733)
Artificial intelligence (199)
Autoimmune disease (77)
Automation (10)
Bankruptcy (147)
Best Places to Work (4608)
BIOSECURE Act (2)
Biosimilars (64)
Biotechnology (18)
Bladder cancer (115)
Brain cancer (35)
Breast cancer (279)
Cancer (2663)
Cardiovascular disease (172)
Career advice (270)
Career pathing (6)
CAR-T (180)
CDC (10)
Celiac Disease (1)
Cell therapy (409)
Cervical cancer (23)
Clinical research (33466)
Collaboration (640)
Compensation (205)
Complete response letters (20)
COVID-19 (786)
CRISPR (36)
C-suite (300)
Cystic fibrosis (67)
Data (3859)
Denatured (4)
Depression (59)
Diabetes (191)
Diagnostics (2360)
Digital health (12)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (87)
Drug pricing (60)
Drug shortages (19)
Duchenne muscular dystrophy (112)
Earnings (35508)
Editorial (20)
Employer branding (1)
Employer resources (19)
Events (33232)
Executive appointments (346)
FDA (8323)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (570)
Gene editing (88)
Generative AI (18)
Gene therapy (259)
GLP-1 (279)
Government (1307)
Grass and pollen (2)
Guidances (288)
Healthcare (6157)
HIV (33)
Huntington's disease (15)
IgA nephropathy (55)
Immunology and inflammation (82)
Immuno-oncology (25)
Indications (64)
Infectious disease (902)
Inflammatory bowel disease (87)
Inflation Reduction Act (6)
Influenza (52)
Intellectual property (159)
Interviews (46)
IPO (8110)
IRA (20)
Job creations (572)
Job search strategy (221)
JPM (11)
Kidney cancer (12)
Labor market (15)
Layoffs (51)
Leadership (6)
Legal (2109)
Liver cancer (51)
Longevity (3)
Lung cancer (349)
Lymphoma (227)
Machine learning (17)
Management (7)
Manufacturing (286)
MASH (97)
Medical device (4765)
Medtech (4789)
Mergers & acquisitions (7329)
Metabolic disorders (502)
Multiple sclerosis (84)
NASH (8)
Neurodegenerative disease (116)
Neuropsychiatric disorders (33)
Neuroscience (1261)
NextGen: Class of 2026 (1506)
Non-profit (717)
Obesity (208)
Opinion (106)
Ovarian cancer (112)
Pain (95)
Pancreatic cancer (147)
Parkinson's disease (124)
Partnered (11)
Patents (299)
Patient recruitment (296)
Peanut (19)
People (15160)
Pharmaceutical (8)
Pharmacy benefit managers (9)
Phase 1 (10746)
Phase 2 (14741)
Phase 3 (10994)
Pipeline (3240)
Policy (73)
Postmarket research (796)
Preclinical (3937)
Press Release (9)
Prostate cancer (128)
Psychedelics (13)
Radiopharmaceuticals (131)
Rare diseases (391)
Real estate (1014)
Recruiting (7)
Regulatory (10370)
Reports (16)
Research institute (534)
Resumes & cover letters (39)
Rett syndrome (22)
RNA editing (5)
RSV (30)
Schizophrenia (74)
Series A (86)
Series B (78)
Service/supplier (2)
Sickle cell disease (48)
Special edition (2)
Spinal muscular atrophy (34)
Sponsored (17)
Startups (685)
Stomach cancer (6)
Supply chain (39)
Tariffs (12)
The Weekly (3)
Vaccines (291)
Venture capital (18)
Weight loss (110)
Women's health (26)
Worklife (5)
Date
Last 7 days (285)
Last 30 days (991)
Last 365 days (15013)
2026 (1386)
2025 (15067)
2024 (16931)
2023 (19102)
2022 (22239)
2021 (23635)
2020 (21800)
2019 (14449)
2018 (10636)
2017 (11459)
2016 (9542)
2015 (11736)
2014 (8102)
2013 (5877)
2012 (6040)
2011 (6749)
2010 (6216)
Location
Africa (182)
Alabama (28)
Alaska (2)
Arizona (77)
Arkansas (3)
Asia (18319)
Australia (5015)
California (5675)
Canada (1852)
China (552)
Colorado (221)
Connecticut (299)
Delaware (131)
Europe (29645)
Florida (870)
Georgia (118)
Hawaii (1)
Idaho (7)
Illinois (370)
India (52)
Indiana (202)
Japan (223)
Kansas (23)
Kentucky (10)
Louisiana (11)
Maine (44)
Maryland (634)
Massachusetts (3855)
Michigan (97)
Minnesota (193)
Missouri (63)
Montana (12)
Nebraska (8)
Nevada (79)
New Hampshire (45)
New Jersey (1804)
New Mexico (4)
New York (1667)
North Carolina (608)
North Dakota (2)
Northern California (2803)
Ohio (118)
Oklahoma (2)
Oregon (9)
Pennsylvania (1127)
Puerto Rico (11)
Rhode Island (11)
South America (304)
South Carolina (42)
Southern California (2257)
Tennessee (68)
Texas (877)
United States (19616)
Utah (131)
Virginia (135)
Washington D.C. (21)
Washington State (527)
West Virginia (2)
Wisconsin (25)
Wyoming (1)
239,785 Results for "nodthera limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
July 22, 2025
·
4 min read
Press Releases
NodThera Announces Appointment of Elisabeth Björk as Board Member
June 17, 2025
·
3 min read
Press Releases
NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
August 12, 2025
·
5 min read
Press Releases
NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1
April 30, 2025
·
5 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
NodThera announces positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters.
June 12, 2024
·
4 min read
Business
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, announces the appointment of Daniel Swisher as Chief Executive Officer, to strengthen the Company’s commercial capabilities, effective immediately.
May 28, 2024
·
5 min read
Press Releases
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
June 4, 2025
·
5 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
NodThera today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).
March 7, 2024
·
5 min read
Press Releases
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
August 5, 2024
·
2 min read
Press Releases
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
August 1, 2024
·
4 min read
1 of 23,979
Next
